FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885350330> ?p ?o ?g. }

• W2885350330 endingPage "1510" @default.
• W2885350330 startingPage "1503" @default.
• W2885350330 abstract "Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain Lynn R Webster,1 Robert J Israel2 1PRA Health Sciences, Salt Lake City, UT, USA; 2Clinical and Medical Affairs, Salix Pharmaceuticals, Bridgewater, NJ, USA Purpose: An oral formulation of methylnaltrexone has been developed for treating opioid-induced constipation (OIC). This manuscript examines the impact of oral methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, on opioid analgesia.Methods: This Phase III, randomized, double-blind, placebo-controlled trial, evaluated changes in pain intensity scores (0= no pain to 10= worst possible pain) and opioid use in adults with chronic noncancer pain. Patients taking ≥50 mg/day oral morphine equivalent dose (MED) for ≥14 days before screening with less than three rescue-free bowel movements/week received oral methylnaltrexone 150 mg/day (n=201), 300 mg/day (n=201), 450 mg/day (n=200), or placebo (n=201) once daily for 4 weeks followed by 8 weeks of oral methylnaltrexone as needed.Results: The primary condition requiring opioid use was back pain (68.2% of 803 patients). Baseline pain intensity scores were similar among treatment groups (mean range, 6.2–6.4) and remained stable throughout the 4-week double-blind (mean range, 6.1–6.5) and 8-week as needed (mean range, 6.3–6.5) periods. Baseline mean MED was comparable between oral methylnaltrexone 150 mg (200.0 mg/day), methylnaltrexone 450 mg (218.0 mg/day), and placebo (209.7 mg/day), but was slightly higher in the oral methylnaltrexone 300-mg group (252.6 mg/day). Nonsignificant, minimal changes in mean MED were observed after 4 weeks of treatment (214.5–235.6 mg/day) and at the end of the as needed phase (202.3–234.9 mg/day). The percentage of patients who initiated new opioid medications during the 4-week, once-daily dosing period was generally similar among the oral methylnaltrexone 150-mg, 300-mg, and 450-mg groups (44.8%, 43.3%, and 35.0%, respectively), the oral methylnaltrexone combined group (41.0%), and the placebo group (39.8%). The most common newly initiated opioid medications during this once-daily period were oxycodone (oral methylnaltrexone groups combined, 14.6%; placebo, 12.4%) and morphine (oral methylnaltrexone combined, 10.1%; placebo, 7.0%).Conclusion: Oral methylnaltrexone does not elicit opioid withdrawal or interfere with opioid analgesia. Keywords: methylnaltrexone, constipation, opioid analgesics, chronic pain, opiate dependence, opioid-related disorders introduction" @default.
• W2885350330 created "2018-08-22" @default.
• W2885350330 creator A5020419303 @default.
• W2885350330 creator A5035384537 @default.
• W2885350330 date "2018-08-01" @default.
• W2885350330 modified "2023-09-27" @default.
• W2885350330 title "Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain" @default.
• W2885350330 cites W142954314 @default.
• W2885350330 cites W1527482428 @default.
• W2885350330 cites W1782609078 @default.
• W2885350330 cites W1849192111 @default.
• W2885350330 cites W1979282061 @default.
• W2885350330 cites W1987755130 @default.
• W2885350330 cites W2010221830 @default.
• W2885350330 cites W2014871043 @default.
• W2885350330 cites W2040109649 @default.
• W2885350330 cites W2055653516 @default.
• W2885350330 cites W2069435922 @default.
• W2885350330 cites W2074029198 @default.
• W2885350330 cites W2097910464 @default.
• W2885350330 cites W2103154281 @default.
• W2885350330 cites W2132309748 @default.
• W2885350330 cites W2143221646 @default.
• W2885350330 cites W2147808981 @default.
• W2885350330 cites W2164341191 @default.
• W2885350330 cites W2169426067 @default.
• W2885350330 cites W2295906267 @default.
• W2885350330 cites W2406100280 @default.
• W2885350330 cites W2554777816 @default.
• W2885350330 cites W2579523544 @default.
• W2885350330 doi "https://doi.org/10.2147/jpr.s160488" @default.
• W2885350330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6095122" @default.
• W2885350330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30147355" @default.
• W2885350330 hasPublicationYear "2018" @default.
• W2885350330 type Work @default.
• W2885350330 sameAs 2885350330 @default.
• W2885350330 citedByCount "11" @default.
• W2885350330 countsByYear W28853503302018 @default.
• W2885350330 countsByYear W28853503302019 @default.
• W2885350330 countsByYear W28853503302020 @default.
• W2885350330 countsByYear W28853503302021 @default.
• W2885350330 countsByYear W28853503302022 @default.
• W2885350330 countsByYear W28853503302023 @default.
• W2885350330 crossrefType "journal-article" @default.
• W2885350330 hasAuthorship W2885350330A5020419303 @default.
• W2885350330 hasAuthorship W2885350330A5035384537 @default.
• W2885350330 hasBestOaLocation W28853503301 @default.
• W2885350330 hasConcept C126322002 @default.
• W2885350330 hasConcept C142724271 @default.
• W2885350330 hasConcept C170493617 @default.
• W2885350330 hasConcept C1862650 @default.
• W2885350330 hasConcept C204787440 @default.
• W2885350330 hasConcept C27081682 @default.
• W2885350330 hasConcept C2781063702 @default.
• W2885350330 hasConcept C2781112942 @default.
• W2885350330 hasConcept C2781118164 @default.
• W2885350330 hasConcept C42219234 @default.
• W2885350330 hasConcept C71924100 @default.
• W2885350330 hasConceptScore W2885350330C126322002 @default.
• W2885350330 hasConceptScore W2885350330C142724271 @default.
• W2885350330 hasConceptScore W2885350330C170493617 @default.
• W2885350330 hasConceptScore W2885350330C1862650 @default.
• W2885350330 hasConceptScore W2885350330C204787440 @default.
• W2885350330 hasConceptScore W2885350330C27081682 @default.
• W2885350330 hasConceptScore W2885350330C2781063702 @default.
• W2885350330 hasConceptScore W2885350330C2781112942 @default.
• W2885350330 hasConceptScore W2885350330C2781118164 @default.
• W2885350330 hasConceptScore W2885350330C42219234 @default.
• W2885350330 hasConceptScore W2885350330C71924100 @default.
• W2885350330 hasLocation W28853503301 @default.
• W2885350330 hasLocation W28853503302 @default.
• W2885350330 hasLocation W28853503303 @default.
• W2885350330 hasLocation W28853503304 @default.
• W2885350330 hasOpenAccess W2885350330 @default.
• W2885350330 hasPrimaryLocation W28853503301 @default.
• W2885350330 hasRelatedWork W1971671270 @default.
• W2885350330 hasRelatedWork W1984226278 @default.
• W2885350330 hasRelatedWork W2003081769 @default.
• W2885350330 hasRelatedWork W2273352484 @default.
• W2885350330 hasRelatedWork W2350429840 @default.
• W2885350330 hasRelatedWork W2380674154 @default.
• W2885350330 hasRelatedWork W2785990365 @default.
• W2885350330 hasRelatedWork W2923073373 @default.
• W2885350330 hasRelatedWork W4233016836 @default.
• W2885350330 hasRelatedWork W4381158239 @default.
• W2885350330 hasVolume "Volume 11" @default.
• W2885350330 isParatext "false" @default.
• W2885350330 isRetracted "false" @default.
• W2885350330 magId "2885350330" @default.
• W2885350330 workType "article" @default.